<code id='F362AFADDA'></code><style id='F362AFADDA'></style>
    • <acronym id='F362AFADDA'></acronym>
      <center id='F362AFADDA'><center id='F362AFADDA'><tfoot id='F362AFADDA'></tfoot></center><abbr id='F362AFADDA'><dir id='F362AFADDA'><tfoot id='F362AFADDA'></tfoot><noframes id='F362AFADDA'>

    • <optgroup id='F362AFADDA'><strike id='F362AFADDA'><sup id='F362AFADDA'></sup></strike><code id='F362AFADDA'></code></optgroup>
        1. <b id='F362AFADDA'><label id='F362AFADDA'><select id='F362AFADDA'><dt id='F362AFADDA'><span id='F362AFADDA'></span></dt></select></label></b><u id='F362AFADDA'></u>
          <i id='F362AFADDA'><strike id='F362AFADDA'><tt id='F362AFADDA'><pre id='F362AFADDA'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:85
          Adobe

          Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

          In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

          advertisement

          Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Change Healthcare cyberattack shows risk of industry consolidation
          Change Healthcare cyberattack shows risk of industry consolidation

          AdobeChangeHealthcare’srecentcyberattackhashospitals,doctors’offices,andpharmaciesacrossthecountryre

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Departing Stanford president retracts two papers

          MarcTessierLavigne(center)retractedtwoSciencepapersonthedayhisresignationasStanfordpresidenttakeseff